Picanco-Castro Virgínia, Gonçalves Pereira Cristiano, Swiech Kamilla, Ribeiro Malmegrim Kelen Cristina, Tadeu Covas Dimas, Silveira Porto Geciane
Center for Cell-based Therapy CTC, Regional Blood Center of Ribeirão Preto, University of São Paulo , Ribeirão Preto, São Paulo, Brazil.
School of Economics, Business Administration and Accounting, University of São Paulo , Ribeirão Preto, São Paulo, Brazil.
Hum Vaccin Immunother. 2020 Jun 2;16(6):1424-1433. doi: 10.1080/21645515.2019.1689744. Epub 2019 Dec 6.
The purpose of this study is to mine CAR-T patents and therapies under development, to design a landscape of the sector and to understand key therapy segments and their current trends. The study analyzed the entire market, consisting of 1624 patent families and 509 biologics under development, to depict an overview of the CAR-T therapies and their state of the art. Our results showed cutting-edge inventions, the major players, the dynamics of cooperation among institutions, the progress of the therapies' generation over the years and future innovation pathways. CAR-T therapies are transforming the current scenario for cancer treatment, and this study reveals the picture of what we can likely expect ahead in order to assist scientists at the academy and industry to improve their research strategies.
本研究的目的是挖掘嵌合抗原受体T细胞（CAR-T）专利及正在研发的疗法，勾勒该领域的全景，了解关键治疗领域及其当前趋势。该研究分析了整个市场，包括1624个专利家族和509种正在研发的生物制剂，以描绘CAR-T疗法及其技术现状的概况。我们的研究结果展示了前沿发明、主要参与者、机构间的合作动态、这些疗法多年来的发展进程以及未来的创新途径。CAR-T疗法正在改变当前癌症治疗的局面，本研究揭示了我们未来可能预期的情况，以帮助学术界和产业界的科学家改进他们的研究策略。
